Bayer is paying $17.5 million upfront to US biotech Arvinas, tapping into a protein-targeting platform to seek new drugs for cardiovascular and gynaecological diseases and cancer, as well a
The FDA has granted Breakthrough Therapy Designation to Bayer’s PI3K inhibitor Aliqopa (copanlisib) for marginal zone lymphoma (MZL) patients who have received two prior therapies.
An entirely new category of medicine is emerging, and a new wave of digital therapeutics start-ups is joining the effort to bring meaning and definition to this new industry.
